(MENAFN- GetNews)


"Brain Monitoring Devices Market"Brain Monitoring Devices market is expected to rise in the upcoming years owing to various factors during the study period, estimates DelveInsight.

The global brain monitoring devices market, estimated at USD 5.89 billion in 2023, is expected to grow at a CAGR of 7.27% from 2024 to 2030, reaching approximately USD 9.13 billion by 2030. This growth is primarily attributed to the rising incidence of neurological conditions such as multiple sclerosis, epilepsy, and dementia, coupled with growing awareness and continuous innovation in product development, all of which are fueling market expansion during the forecast period.

DelveInsight's Brain Monitoring Devices Market Insights report offers a detailed analysis of current and forecasted market trends, market share of key players, drivers and barriers, industry challenges, and emerging trends, providing a comprehensive overview of the competitive landscape in the global brain monitoring devices market.

Request for a sample page report @

Key Takeaways from the Brain Monitoring Devices Market Report

The Brain Monitoring Devices market is expected to witness moderate growth at a steady CAGR between 2025 and 2032. According to DelveInsight's estimates, North America is projected to remain the leading region in the global market throughout the forecast period.

Several prominent companies are actively shaping the competitive landscape, including Medtronic, Nonin, Raumedic AG, Natus Medical Incorporated, Edwards Lifesciences Corporation, BrainScope Company Inc., NIHON KOHDEN CORPORATION, Neurosoft, Advanced Brain Monitoring Inc., Rimed, Masimo, NeuroWave Systems Inc., Compumedics Limited, Spiegelberg GmbH & Co. KG, NOVASIGNAL CORPORATION, and others.

Key recent developments include:

• June 2024: Zeto received FDA clearance for its user-friendly EEG brain monitoring system, designed with a comfortable headset that can be used by healthcare professionals with minimal training.

• April 2024: NeuroVigil launched the iBrain personal brain monitor in the U.S.-an investigational, portable device for noninvasive brain electrical activity recording in patients with neurological disorders.

• May 2024: Neurable secured $13 million in funding to enhance its non-invasive brain-computer interface (BCI) technology, which integrates EEG and AI in a compact design to capture and analyze brain activity data.

• April 2021: Integra LifeSciences Corporation obtained FDA 510(k) clearance for its CereLink ICP Monitor, a device that connects standard physiological pressure monitoring systems with compatible strain-gauge pressure transducers.

To read more about the latest highlights related to the Brain Monitoring Devices market, get a snapshot of the key highlights entailed in the Global Brain Monitoring Devices Market Report

Brain Monitoring Devices Overview

Brain monitoring devices are medical instruments designed to measure and evaluate various aspects of brain activity, including electrical signals, blood flow, and intracranial pressure. These devices are essential for diagnosing neurological conditions, tracking disease progression, supporting treatment decisions, and monitoring patient recovery across both clinical practice and research environments.

Brain Monitoring Devices Market Insights

North America is projected to maintain a dominant position in the brain monitoring devices market between 2024 and 2030, primarily driven by the rising prevalence of Parkinson's disease, a growing number of traumatic brain injury (TBI) cases, and active product innovation supported by regulatory approvals. Additionally, the strong presence of key market players in the region further accelerates market expansion.

According to the Parkinson's Foundation (2024), nearly one million individuals in the U.S. are currently living with Parkinson's disease, a number expected to increase to 1.2 million by 2030. As the second most common neurodegenerative disorder after Alzheimer's, Parkinson's sees approximately 90,000 new diagnoses annually in the country. Brain monitoring devices play an essential role in diagnosing the condition, tracking its progression, and evaluating treatment efficacy. These technologies provide valuable insights into motor and cognitive functions, facilitating personalized treatment approaches and the development of targeted therapeutic interventions America is projected to maintain a dominant position in the brain monitoring devices market between 2024 and 2030, primarily driven by the rising prevalence of Parkinson's disease, a growing number of traumatic brain injury (TBI) cases, and active product innovation supported by regulatory approvals. Additionally, the strong presence of key market players in the region further accelerates market expansion.

According to the Parkinson's Foundation (2024), nearly one million individuals in the U.S. are currently living with Parkinson's disease, a number expected to increase to 1.2 million by 2030. As the second most common neurodegenerative disorder after Alzheimer's, Parkinson's sees approximately 90,000 new diagnoses annually in the country. Brain monitoring devices play an essential role in diagnosing the condition, tracking its progression, and evaluating treatment efficacy. These technologies provide valuable insights into motor and cognitive functions, facilitating personalized treatment approaches and the development of targeted therapeutic interventions.

To know more about why North America is leading the market growth in the Brain Monitoring Devices market, get a snapshot of the Brain Monitoring Devices Market Outlook

Brain Monitoring Devices Market Dynamics

According to World Health Organization (WHO) 2023 data, more than 1.8 million people worldwide are affected by multiple sclerosis (MS)-a neurological disorder in which the immune system attacks the brain and spinal cord, leading to cognitive, emotional, sensory, motor, and visual impairments. Brain monitoring devices are essential in tracking brain activity and function, facilitating accurate diagnosis, monitoring disease progression, and evaluating treatment outcomes, ultimately supporting personalized patient care.

Furthermore, WHO 2024 data highlights that approximately 50 million individuals globally are living with epilepsy, making it one of the most widespread neurological conditions, with nearly 80% of cases occurring in low- and middle-income countries. Research suggests that up to 70% of epilepsy cases could achieve seizure control with proper diagnosis and treatment. Each year, an estimated 5 million new cases are reported worldwide, with incidence rates of about 49 per 100,000 in high-income nations and up to 139 per 100,000 in lower-income regions. Brain monitoring devices play a pivotal role in epilepsy diagnosis, seizure tracking, treatment planning, and therapy evaluation, significantly enhancing disease management and patient outcomes.

Brain Monitoring Devices Market Drivers:

• Increasing instances of neurological disorders

• Rising product developmental activities

Get a sneak peek at the Brain Monitoring Devices market dynamics

Scope of the Brain Monitoring Devices Market Report:

• Coverage: Global

• Study Period: 2022 to 2032

• Key Brain Monitoring Devices Companies: Medtronic, Nonin, Raumedic AG, Natus Medical Incorporated, Edwards Lifesciences Corporation, BrainScope Company Inc., NIHON KOHDEN CORPORATION, Neurosoft, Advanced Brain Monitoring Inc., Rimed, Masimo, NeuroWave Systems Inc., Compumedics Limited, Spiegelberg GmbH & Co. KG, NOVASIGNAL CORPORATION, and others.

Which MedTech key players in the Brain Monitoring Devices market are set to emerge as the trendsetter, explore @ Brain Monitoring Devices Companies

About DelveInsight

DelveInsight is a premier healthcare business consultant and market research firm, specializing in life sciences. We empower pharmaceutical companies with comprehensive end-to-end solutions designed to enhance performance and drive growth.

Our expert healthcare consulting services offer in-depth market analysis, helping businesses accelerate growth and navigate challenges with actionable, results-driven strategies.

MENAFN03112025003238003268ID1110288818